Fasting days with ≈500 kcal alternating with days of normal eating.
Randomized trial (80 patients with metabolic syndrome, 4 months): modified alternate-day fasting achieved more weight loss and a greater drop in inflammation (hs-CRP) than classic calorie restriction. A modest result that needs confirmation.
View the study (study) →Randomized trial: 4 weeks of strict alternate-day fasting cut calories by 37%, improved cardiovascular markers, lowered fat (especially trunk fat), and raised beta-hydroxybutyrate even on eating days. No adverse effects at more than 6 months.
View the study →⏱ 3 min read
Alternate-day fasting, or ADF, is a form of intermittent caloric restriction in which days of near-complete fasting (typically 0-500 kcal on a modified fasting day or 0 kcal on a complete fasting day) alternate with days of free eating (without explicit caloric restriction); it is one of the most clinically studied variants of intermittent fasting, along with 16:8 fasting (daily time-restricted eating within an 8-hour window), 5:2 fasting (2 days of modified fasting per week on nonconsecutive days), and occasional prolonged fasting (24-72+ hours).
Unlike 16:8 fasting (which keeps a daily eating distribution with a time restriction), ADF imposes a more significant alternation of metabolic "poles": fasting days produce a deeper activation of the metabolic pathways associated with fasting (autophagy, mild ketogenesis, sustained lipolysis), while free-eating days allow enough intake to maintain muscle mass and micronutrients; this alternation is more intense but also more cognitively and socially demanding than daily time-restricted approaches.
The best-studied clinically supported indication is weight loss in adults with overweight or obesity: several randomized trials and meta-analyses have documented significant losses with ADF over 8-24 weeks, with magnitudes comparable to those of traditional continuous caloric restriction when the total weekly caloric deficit is equivalent; the data suggest that most people do not fully compensate on free-eating days for the restriction of fasting days, producing a net caloric deficit sufficient for clinical weight loss.
Several studies have documented significant improvements in insulin sensitivity, fasting glucose, and other metabolic markers with ADF over weeks to months, an indication consistent with the general improvement seen with any caloric restriction effective for weight loss.
In lipid profile (especially triglycerides and LDL), the effects of ADF are favorable and comparable to those of other caloric restriction interventions; improvements are seen at clinically relevant magnitudes during the first month and are maintained as long as the weight loss is maintained.
The TREAT trial published in JAMA Internal Medicine in 2020 directly compared ADF with continuous daily caloric restriction over 12 months, finding no significant differences in weight loss or metabolic improvements at one year between the two strategies; these data suggest that the choice between fasting modalities and continuous caloric restriction should be based mainly on individual preference and clinical adherence rather than on a clear mechanistic superiority of one over the other.
The most studied modalities are: strict ADF (0 kcal on fasting days), modified ADF (0-500 kcal on fasting days, typically one small meal; this form is more sustainable for most people), and "5:2" (a weekly variant with 2 days of modified fasting and 5 days of free eating); gradual introduction (starting with one day a week of restriction and increasing gradually) eases adaptation; hydration is critical on fasting days; coffee and unsweetened tea are allowed; free-eating days are not a license for uncontrolled excess but days of normal eating according to usual nutritional needs.
Safety considerations are important: fasting is contraindicated in pregnancy, breastfeeding, type 1 diabetes, active eating disorders or a recent history of them, malnutrition or significantly low weight, critical illness or convalescence, and in people on medication that must be taken with regular meals (especially some antidiabetic drugs); people with type 2 diabetes treated with insulin or secretagogues require careful dose adjustment under medical supervision to avoid hypoglycemia; older adults with sarcopenia or at risk of frailty should maintain adequate protein intake on free-eating days (1.2-1.6 g/kg/day) to avoid accelerated muscle loss; children and adolescents should not practice intermittent fasting except under specific medical supervision; the most frequent adverse effects in healthy people are headache, fatigue, mild dizziness, irritability, and difficulty concentrating during the first days or weeks, typically transient; the reasonable clinical position is that ADF is one of several valid tools for weight loss and metabolic improvement in appropriately selected people, with efficacy similar to other caloric restriction interventions and with an adherence profile that varies according to individual preferences.
Information, not medical advice. Scientific evidence reflects the quality of the studies.